Bruce Broussard and Karen Lynch joining Optura as Strategic Advisors

They join a broader group of advisors with experience from Humana, Optum, UnitedHealth Group, Horizon Blue Cross Blue Shield, BlueCross BlueShield of Tennessee, and Boston Consulting Group.

Healthcare organizations have been investing in enterprise AI for more than a year, but many still struggle to answer a key question: Is it delivering results? While AI adoption is widespread, many organizations have not been able to measure its impact on business performance clearly.

Studies have shown that only a limited number of organizations report meaningful financial benefits from AI, and many generative AI pilot projects have produced little measurable impact on profits and losses. As healthcare companies continue to invest heavily in AI, proving its value has become a critical business challenge.

Karen Lynch, who helped transform CVS Health into a more customer-focused healthcare company, believes AI should deliver real and measurable results. She said that AI’s true value lies in improving care, access, and outcomes, and that organizations need tools to turn AI investments into productivity, innovation, and meaningful business results.

Read More:NileBuilt® Acquisition Pursuit & Strategic Advisors

Together, Broussard and Lynch bring more than 100 years of combined healthcare leadership experience. They share the view that measuring the return on AI investment (ROAI) is essential for the industry. They are joined by a team of advisors who have held leadership roles in major healthcare organizations and have experience managing financial, operational, and technology functions while scaling AI programs.

Broussard, who grew Humana from $39 billion to nearly $93 billion in revenue over more than a decade as CEO and currently serves on the board of Cleveland Clinic, puts it plainly: "Healthcare leaders are making important investments in innovation and transformation, but measuring what's truly creating value remains a challenge. ROAI provides a much-needed framework for connecting investment to impact, and Optura is building it the right way."

"The advisors who've aligned with Optura have run the largest healthcare organizations in the country, where the stakes of getting AI wrong aren't measured in wasted budget. They're measured in people's health," said Andy Fanning, Co-Founder and CEO of Optura. "That's the lens this platform was built from."

About Optura

Founded in 2024 by Andy Fanning and Mike Hollis, Optura is a healthcare technology platform focused on helping organizations measure the Return on AI Investment (ROAI™). The platform helps healthcare leaders identify where AI investments can deliver the greatest value. Using an organization’s existing workflows and standard operating procedures, Optura creates AI-powered solutions, estimates potential returns before implementation, and tracks actual performance through a unified intelligence platform.

Read More:Arsenal Capital Partners Adds Max Schechter as Head of Industrial Growth Business Development